お知らせ • Jun 30
Sinocelltech Group Limited to Report First Half, 2026 Results on Aug 29, 2026 Sinocelltech Group Limited announced that they will report first half, 2026 results on Aug 29, 2026 Board Change • May 20
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Xue Zhang was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. お知らせ • Apr 23
Sinocelltech Group Limited, Annual General Meeting, May 13, 2026 Sinocelltech Group Limited, Annual General Meeting, May 13, 2026, at 14:30 China Standard Time. Location: R and D Building, No. 31, Kechuang 7th Street, Economic and Technological Development Zone, Beijing China お知らせ • Mar 30
Sinocelltech Group Limited to Report Q1, 2026 Results on Apr 30, 2026 Sinocelltech Group Limited announced that they will report Q1, 2026 results on Apr 30, 2026 お知らせ • Dec 26
Sinocelltech Group Limited to Report Fiscal Year 2025 Results on Apr 23, 2026 Sinocelltech Group Limited announced that they will report fiscal year 2025 results on Apr 23, 2026 お知らせ • Sep 30
Sinocelltech Group Limited to Report Q3, 2025 Results on Oct 31, 2025 Sinocelltech Group Limited announced that they will report Q3, 2025 results on Oct 31, 2025 お知らせ • Jun 30
Sinocelltech Group Limited to Report First Half, 2025 Results on Aug 29, 2025 Sinocelltech Group Limited announced that they will report first half, 2025 results on Aug 29, 2025 お知らせ • Jun 06
Sinocelltech Group Limited announced that it expects to receive CNY 900 million in funding from Lhasa Alike Investment Consulting Co., Ltd. Sinocelltech Group Limited announced that it has entered into a securities purchase agreement to issue not more than 25,000,000 shares at a price of CNY 36 per share for the gross proceeds of CNY 900,000,000 on June 5, 2025. The transaction will include participation from Lhasa Alike Investment Consulting Co., Ltd. The transaction has been approved by the shareholders of the company in the third board of directors of the company. The transaction is subjected to approval of the company's shareholders' meeting, approval of the Shanghai Stock Exchange, approval of the Shanghai Stock Exchange. お知らせ • Apr 26
Sinocelltech Group Limited, Annual General Meeting, May 16, 2025 Sinocelltech Group Limited, Annual General Meeting, May 16, 2025, at 14:30 China Standard Time. Location: R and D Building, No. 31, Kechuang 7th Street, Economic and Technological Development Zone, Beijing China お知らせ • Mar 28
Sinocelltech Group Limited to Report Q1, 2025 Results on Apr 26, 2025 Sinocelltech Group Limited announced that they will report Q1, 2025 results on Apr 26, 2025 お知らせ • Dec 27
Sinocelltech Group Limited to Report Fiscal Year 2024 Results on Apr 26, 2025 Sinocelltech Group Limited announced that they will report fiscal year 2024 results on Apr 26, 2025 Reported Earnings • Oct 29
Third quarter 2024 earnings released: EPS: CN¥0.057 (vs CN¥0.18 loss in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.057 (up from CN¥0.18 loss in 3Q 2023). Revenue: CN¥632.3m (up 11% from 3Q 2023). Net income: CN¥24.2m (up CN¥106.4m from 3Q 2023). Profit margin: 3.8% (up from net loss in 3Q 2023). Revenue is forecast to grow 28% p.a. on average during the next 2 years, compared to a 26% growth forecast for the Biotechs industry in China. New Risk • Sep 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CN¥389m free cash flow). Negative equity (-CN¥465m). Minor Risk Share price has been volatile over the past 3 months (7.5% average weekly change). お知らせ • Sep 30
Sinocelltech Group Limited to Report Q3, 2024 Results on Oct 29, 2024 Sinocelltech Group Limited announced that they will report Q3, 2024 results on Oct 29, 2024 Reported Earnings • Aug 22
Second quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.034 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.11 (up from CN¥0.034 in 2Q 2023). Revenue: CN¥692.2m (up 44% from 2Q 2023). Net income: CN¥51.5m (up 240% from 2Q 2023). Profit margin: 7.4% (up from 3.2% in 2Q 2023). Revenue is forecast to grow 26% p.a. on average during the next 2 years, compared to a 22% growth forecast for the Biotechs industry in China. お知らせ • Jun 29
Sinocelltech Group Limited to Report First Half, 2024 Results on Aug 22, 2024 Sinocelltech Group Limited announced that they will report first half, 2024 results on Aug 22, 2024 Reported Earnings • Apr 26
First quarter 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.34 loss in 1Q 2023) First quarter 2024 results: EPS: CN¥0.17 (up from CN¥0.34 loss in 1Q 2023). Revenue: CN¥612.5m (up 86% from 1Q 2023). Net income: CN¥74.2m (up CN¥227.2m from 1Q 2023). Profit margin: 12% (up from net loss in 1Q 2023). Revenue is forecast to grow 28% p.a. on average during the next 2 years, compared to a 22% growth forecast for the Biotechs industry in China. お知らせ • Apr 13
Sinocelltech Group Limited, Annual General Meeting, May 07, 2024 Sinocelltech Group Limited, Annual General Meeting, May 07, 2024, at 14:30 China Standard Time. お知らせ • Mar 29
Sinocelltech Group Limited to Report Q1, 2024 Results on Apr 26, 2024 Sinocelltech Group Limited announced that they will report Q1, 2024 results on Apr 26, 2024 Reported Earnings • Feb 24
Full year 2023 earnings released: CN¥0.89 loss per share (vs CN¥1.19 loss in FY 2022) Full year 2023 results: CN¥0.89 loss per share (improved from CN¥1.19 loss in FY 2022). Revenue: CN¥1.89b (up 85% from FY 2022). Net loss: CN¥396.0m (loss narrowed 24% from FY 2022). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. New Risk • Feb 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Negative equity (-CN¥439m). Minor Risk Share price has been volatile over the past 3 months (7.6% average weekly change). Reported Earnings • Nov 01
Third quarter 2023 earnings released: CN¥0.18 loss per share (vs CN¥0.34 loss in 3Q 2022) Third quarter 2023 results: CN¥0.18 loss per share (improved from CN¥0.34 loss in 3Q 2022). Revenue: CN¥571.2m (up 108% from 3Q 2022). Net loss: CN¥82.1m (loss narrowed 46% from 3Q 2022). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in China. Reported Earnings • Aug 24
Second quarter 2023 earnings released: EPS: CN¥0.034 (vs CN¥0.25 loss in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.034 (up from CN¥0.25 loss in 2Q 2022). Revenue: CN¥479.3m (up 118% from 2Q 2022). Net income: CN¥15.2m (up CN¥122.2m from 2Q 2022). Profit margin: 3.2% (up from net loss in 2Q 2022). Revenue is forecast to grow 31% p.a. on average during the next 2 years, compared to a 22% growth forecast for the Biotechs industry in China. Board Change • Mar 15
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director Wei He was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.